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The USFDA approved ‘‘epigenetic drug’’, Decitabine, exerts its effect by hypomethylating DNA,
demonstrating the pivotal role aberrant genome-wide DNA methylation patterns play in cancer ontology.
Using sensitive technologies in a cellular model of Acute Myeloid Leukemia, we demonstrate that while
Decitabine reduces the global levels of 5-methylcytosine (5mC), it results in paradoxical increase of
5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) levels. Hitherto,
the only biological mechanism known to generate 5hmC, 5fC and 5caC, involving oxidation of 5mC by
members of Ten-Eleven-Translocation (TET) dioxygenase family, was not observed to undergo any
alteration during DAC treatment. Using a multi-compartmental model of DNAmethylation, we show that
partial selectivity of TET enzymes for hemi-methylated CpG dinucleotides could lead to such alterations in
5hmC content. Furthermore, we investigated the binding of TET1-catalytic domain (CD)-GFP to DNA by
Fluorescent Correlation Spectroscopy in live cells and detected the gradual increase of the DNA bound
fraction of TET1-CD-GFP after treatment with Decitabine. Our study provides novel insights on the
therapeutic activity of DAC in the backdrop of the newly discovered derivatives of 5mC and suggests that
5hmChas the potential to serve as a biomarker formonitoring the clinical success of patients receivingDAC.
A berrant DNA methylation, such as hypermethylation of tumor suppressor genes, is a hallmark of cancerand a testament to the role of epigenetics in oncogenesis1–3. Epigenetic alterations on genes that regulatethe differentiation of hematopoietic stem cells (HSCs) into matured blood cells, clinically christened
hematopoiesis, are frequently observed in myeloid malignancies4–8. The recent discovery of the 5mC derivative,
5hmC9,10, in addition to its sub-derivatives, 5fC and 5caC11 (Figure 1a), has produced new players that could
participate in epigenetic regulation of transcription10,12–15. The USFDA approved hypomethylating agent,
Decitabine (5-aza-29-deoxyctidine; Dacogen; DAC), removes 5mCmarks through depletion of the maintenance
methyltransferase DNMT1 in the cell. Although intuitively one would assume that DAC would induce demethy-
lation randomly, data from colon cancer (HCT116) and HL-60 cell lines suggest that some loci may be protected
from DAC-induced demethylation16,17.
During the semi-conservative DNA replication, DNMT1 is primarily responsible for transmitting the fidelity
of cytosine methylation to the daughter cells16,18. Fully methylated CpG dinucleotides (5mC/5mC) are transiently
transformed into hemi-methylated CpGs (5mC/C) that are recognized by DNMT1 and converted to fully
methylated dinucleotides, thereby restoring the parental DNA methylation pattern (5mC/5mC)19. DNMT3A
and 3B are traditionally recognized for their role as de novo DNA methyltransferases during early development
and differentiation, although recently it has been proposed that DNMT3A and 3B may be involved in the
DNMT1-mediated methylation process19. However, the only known mechanism facilitating the conversion of
5mC into 5hmC is mediated by members of the ten-eleven-translocation family of dioxygenase enzymes
(TET 1, 2 and 3) via an Fe(II) and a-ketoglutarate (a-KG)-dependent oxidation reaction10. Loss-of-functional
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mutations in TET2 occur frequently in Myelodysplastic Syndromes
(MDS) and Acute Myeloid Leukemia (AML)6,7,20, and are mutually
exclusive of mutations in IDH1/2, whose aberrant product, 2-hydro-
xyglutarate, inhibits TET-mediated conversion of 5mC to 5hmC21.
Mutations in DNMT3A are found in 22% of de novo AML cases7
where they sometimes are accompanied bymutations in either TET2
or IDH1/2, confirming the role of DNA methylation in normal
hematopoiesis and leukemogenesis.
Although the precise molecular mechanism of DAC action is not
completely understood, DAC is a structural analogue of cytosine and
can easily be incorporated as its substitute in DNA during replica-
tion22. DNMT1 recognizes these Decitabine-Guanine dinucleotides
as a natural substrate and initiates amethyltransferase reaction, but is
trapped in the process23. This leads to depletion of DNMT1 from the
cell, loss of maintenance methylation and ‘passive demethylation’ of
genomic DNA following cell division16–18. The precisemode ofmain-
taining 5hmC patterns during DNA replication is not known.
Although TET proteins have been demonstrated to be capable of
catalyzing both hemi-methylated and fully-methylated CpGs10, it is
not clear if the TET proteins display a selective preference for hemi-
methylated or fully-methylated CpG dinucleotides in cells.
In our present effort, we have studied the effects of DAC on the
downstream derivatives of 5mC. Our study suggests a possible
mechanism of action of DAC on 5mC derivatives, which could fur-
ther our understanding of the effect of hypomethylating drugs and
epigenetic therapies. To shed light on our observations, we employed
a multi-compartmental model to mathematically interpret the DNA
methylome changes and the underlying activities of TETs uponDAC
treatment in human leukemia cells. We have also presented evidence
in favor of our model, using advanced fluorescence microscopy and
spectroscopy that has the ability to capture real-time single-molecule
dynamics of TET proteins in living cells.
Results
Quantification of 5mC and 5hmC in HL-60 cells upon DAC
treatment. Initially, we sought to determine the changes in the
patterns of methyl-CpG-binding domain proteins (MBDs) in
response to DAC, which led us to the unexpected observation that
the 5hmC content in HL-60 cells increased in response to DAC. HL-
60 cells, a well-studied acute myeloid leukemia cell line24,25, were
treated with 0.5 mM and 3 mM DAC for 40 hours. The
concentration of the drug used in our study closely resembles the
range of maximum concentrations (Cmax) of DAC observed in
human plasma at clinically administered dosages26,27. In untreated
HL-60 cells, 5mC is localized at specific loci whereas 5hmC appears
to be more dispersed throughout the nucleus. The reduction in the
Figure 1 | The effect of DAC on 5mC and 5hmC in HL-60 cells. (a) The scheme of mammalian ‘active demethylation’ pathway.
(b) Immunocytochemistry for 5mC (green channel) and 5hmC (red channel) performed on untreated and 3 mMDAC treated HL-60 cells. The scale bar
denotes 5 mm. (c & d) Global levels of 5mC and 5hmC by EIA respectively in untreated, 0.5 mMand 3 mMDAC treatedHL-60 cells. The limit of detection
of 5mCwas 5 pg/100 ng of addedDNA, while that for 5hmCwas 2 pg/200 ng of addedDNA. (e & f) LC-MS/MS quantitation of levels of 5mC and 5hmC
in terms of ratios of 5-methyl-29-deoxycytidine (5mdC) or 5-hydroxymethyl-29-deoxycytidine (5hmdC) to those of deoxycytidine (dC) respectively in
untreated, 0.5 mM and 3 mM DAC treated HL-60 cells. Limits of Detection (LOD) of 5mdC and 5hmdC were 0.09 and 0.11 fmol respectively.
www.nature.com/scientificreports
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number of 5mC foci and appearance of more 5hmC foci upon
DAC treatment is also visualized by immunofluorescence images
(Figure 1b). Global analysis of DNA methylation by Enzyme-based
Immunoassay (EIA) conceptualized in our lab28, revealed reduction
in the levels of 5mC (Figure 1c) along with an increase in the levels
5hmC, following treatment (Figure 1d). In addition to the EIA
quantification, liquid chromatography-tandem mass spectrometry
(LC-MS/MS) analysis was used to further validate our observation
of a decrease of 5mC and increase of 5hmC upon DAC treatment.
We determined that the 5mdC/dC percentage in control, 0.5 mM
DAC-treated and 3 mM DAC-treated HL-60 cells are 5.02%, 2.15%
and 1.88% respectively (Figure 1e). By contrast, an increasing trend
of the percentage of 5hmdC/dC was noted: from 0.0015% in control
cells to 0.0025% in 0.5 mM DAC-treated cells, and to 0.0037% in
3 mM DAC-treated cells (Figure 1f). Recently it has been reported
that, in addition to 5hmC, the TET proteins also generate 5fC and
5caC11. Interestingly, we observed a relative increase in the levels of
5fC and 5caC in HL-60 cells treated with DAC compared to control
cells (Supplementary Figures 1a, b & c).
Assessment of DNMTs and TETs. To elucidate the mechanism of
DAC-induced methylation changes, we measured the effect of DAC
on the expression of DNMT and TET family members. While no
significant changes in DNMT1, TET1, TET2 and TET3 transcript
levels were observed, the steady state levels of DNMT3A and
DNMT3B increased by 3.62 fold and 4.42 fold, (P , 0.05, two-
tailed t-test respectively (Figures 2a & b). In contrast, at the
protein level, we detected a near-complete reduction of DNMT1
(as expected), while DNMT3A and DNMT3B protein levels were
unchanged (Figure 2c).
Multi-compartmental modeling of TETs in DAC treated cells.We
modified a recent mathematical model (Figure 3a)29 to study the
dynamics of methylation and demethylation and applied it to
analyze the effect of DAC in machina and found that elimination
of DNMT1 activity results in an increase of hemi-methylated CpG
dinucleotides and loss of fully methylated CpG dinucleotides. The
net effect of this change is a reduction in overall methylation levels
and a corresponding reduction in 5hmC levels (Figure 3b). This
global reduction of 5hmC is in contrast to our experimental data.
However, an assumption of this mathematical analysis is that the
TET proteins have equal affinity for both hemi-methylated and fully
methylated CpG dinucleotides29. We therefore proposed that
selective activity of TET for hemi-methylated dinucleotides
(which have increased abundance after DAC treatment) could
explain the apparent paradoxical increase of 5hmC, and extended
our models to investigate this effect. Further, from our
mathematical models, when TET was defined as being fully
selective for hemi-methylated dinucleotides, cells treated in
machina with DAC were found to have a dramatic increase in
5hmC levels (Figure 3c). However the pretreatment abundance of
5hmC in this system was substantially lower than experimentally
reported levels10, suggesting that TET is unlikely to be fully selective
for hemi-methylated DNA. In models where TET was defined as
being partially selective for hemi-methylated dinucleotides, 5hmC
levels were maintained in untreated cells yet increased in cells
treated with DAC (Figure 3d). Alteration of the relative activity of
TET on hemi-hydroxymethylated/hemi-methylated (5hmC/5mC)
CpG dinucleotides had minimal effect on the overall levels of
methylation or hydroxymethylation, primarily due to the low
relative abundance of these dinucleotides. We further extended our
model to show preliminary evidence of the effect of DAC on
downstream derivatives of 5hmC (Figure 3a), namely 5fC and
5caC11, and found that an increased abundance of these minority
nucleotides was also observed after DAC treatment (Figure 3e),
consistent with our experimental data (Supplementary Figure 1).
Single-molecule dynamics of TET1-CD-GFP after DAC treatment
by Fluorescent Correlation Spectroscopy (FCS). In order to
experimentally support our modeling hypothesis, we constructed a
GFP tagged TET1-CD (the domain shared by all other TET proteins)
to inspect its DNA binding properties upon DAC incorporation.
Following the molecular cloning and transfection of TET1-CD-
GFP, we conducted FCS in MCF7 cells treated with DAC at
different time points (Figures 4a & b). In the nucleus of untreated
control cells, with an average expression of TET1-CD-GFP at
,200 nM, the diffusion times for free and bound TET1-CD-GFP
are 1.79 6 0.23 ms and 24.84 6 5,74 ms, respectively. Notably, the
free proteins constitute the predominant group – a percentage of
Figure 2 | Molecular profiling of changes occurring during DAC
treatment. (a & b) The transcriptional changes, measured by qPCR, of in
DNMT1, DNMT3A, DNMT3B, TET1, TET2 and TET3 in 0.5 mM and
3 mM DAC treated HL-60 cells, respectively, compared to their levels in
untreated HL-60 cells. All values have been normalized with GAPDH/b-
actin (c)Western Blot analysis to understand the precise effect onDNMTs.
b-actin is shown as a protein loading control.
www.nature.com/scientificreports
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,73% (Supplementary Figure 2). With a gradual incorportation of
DAC to generate hemi-methylated dyad alongwithDNA replication,
a significant increase in the bound form of TET1-CD-GFPwas noted
from 30 hours. At 40 hours, the bound TET1-CD-GFP became the
major diffusing form, accounting for a percentage of ,76%
(Figure 4c). This result suggests that even although DAC treatment
did not alter the amount of TET proteins, the DNA bound fraction of
TET increased significantly while the free TET proteins decreasd
simultaneously after DAC treatment, which in turn may cause an
increase in 5hmC (Figure 4d).
Discussion
The ‘‘epigenetic drug’’, Decitabine has a dose-dependent mode of
action30. While at higher doses, it is a potent cytotoxic agent; at chem-
ically administered lower doses, it is an effective anti-tumour agent30–32.
Elaborate studies involvingNext-Generation Sequencing of the reduc-
tion in global levels of 5mC in leukemia cells treatedwithDAC indicate
non-random patterns of demethylation16–18, with an unexplained up-
regulation of genes involved in differentiation16 and those involved in
tumor suppression (P15/CDKN2B33, TP7333, Cadherin133,34, MLH135
and P16/CDKN2A36). However, the discovery of downstream
derivatives of 5mC, namely, 5hmC, 5fC and 5caC compelled us to
re-investigate the effect of DAC on these novel epigenetic marks.
The low dosage of DAC administered in our study led to a mild
inhibition in the rate of cellular proliferation (Supplementary
Figure 3); minor differences in the cell cycle and apoptotic profile
(Supplementary Figure 4a & b), and reduction in levels of 5mC
(Figure 1c & e) compared to control, consistent with previous
reports17,30,37. On the other hand, we report the very first observation
of an increase of 5hmC content in DAC treated HL-60 cells
(Figure 1d & f). While trapping of DNMT1 proteins followed by
proteasomal degradation in the presence of DAC has been demon-
strated experimentally18, there is controversy regarding the effect of
DAC on DNMT3A and DNMT3B38–40. We were perplexed by the
incongruence between steady-state mRNA and protein levels of
DNMT3A andDNMT3B followingDAC exposure. However, a tran-
scription independent decrease in DNMT3A protein levels has been
reported in hypomethylated cells with impaired DNMT1 activity41,
which supports our findings. We found no significant alterations in
TET1, TET2 and TET3 transcript levels following DAC exposure.
A number of mathematical models have attempted to capture the
complexmechanisms involved inmethylation42,43 andmore recently,
have included the ‘active demethylation’ effects of the TET proteins
(Figure 3a)29. Our in machina models suggest that the apparent
paradoxical increase in 5hmC levels following DAC treatment of
HL-60 cells can be explained if TET enzymes preferentially act at
Figure 3 | Mathematical simulation using a multi-compartmental model. (a) A schematic representation of the original six compartmental model
components (black) and the extendedmodel components (red). Solid lines indicate epigenetic modification by enzymes. Broken lines indicate the effects
of cell division. The effects of DAC treatment (at time 5 0) in machina on the relative abundance of unmethylated (red), methylated (blue), and
hydroxymethylated (green) CpGs (b) in cells with non-selective TET; (c) in cells with TET proteins which are intrinsically fully selective for hemi-
methylated CpGdinucleotides; (d) in cells with TET partially selective (6-fold) for hemi-methylated CpGdinucleotides; (e) and in cells with TET partially
selective for hemi-methylated CpG dinucleotides demonstrating the effect on abundance of 5fC (purple) and 5caC (brown).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 9281 | DOI: 10.1038/srep09281 4
hemi-methylated rather than fully methylated CpG dinucleotides. It
remains unclear whether this is due to DAC or an intrinsic property
of the TET proteins. Due to the limited availability of tools to study
the dynamics of CpG dinucleotides bearing derivatives of the methy-
lation-demethylation cycle, gathering evidence in support of the
conclusion of the mathematical modeling was a daunting task.
However, we exploited the recent advances in the field of FCS tech-
nique to assess the real-time account of molecular events resulting
during DAC treatment. Biophysically, TET proteins are considered
to have distinct diffusion properties on the basis of whether it is
found freely in the nucleus or bound to the DNA (Supplementary
Figure 2). The confocal alignment of FCS facilitates collection of
fluorescence events in a volume of less than 1 femtoliter at a low
laser power (1 mW) at physiological conditions, giving it a distinctive
advantage over other methods44–49.
TET mediated conversion of methylated and hemi-methylated
oligonucleotides into their hydroxymethylated and hemi-hydroxy-
methylated forms, respectively, has been previously reported10, but
the relative affinities of TET proteins for fully methylated and hemi-
methylated CpGs need to be experimentally determined. In this
regard, we have for the first time, studied the dynamics of TET1-
CD-GFP by FCS in live cells after DAC treatment and have reported
the significant increase in the DNA-bound fraction of TET upon
DAC treatment. Similar to DNMTs41,50,51, in the nucleus, the DNA
bound fraction of TET proteins can be correlated with enzymatic
activity52. Thus, the significant increase of the DNA-bound fraction
of TETs from 27% at 0 hour to 76% after 40 hours of DAC treat-
ment, suggests significant alteration of TET dynamics and its con-
sequent enzymatic activity in cells after administration of DAC.
All of this taken together suggests that the increased recruitment of
TETs on DNA after DAC treatment, possibly at hemi-methylated
dyads, maybe one of the critical factors responsible for the increased
abundance of 5hmC and the other derivatives of 5mC. Thus we
hypothesize that, incorporation of DAC in the context of methylated
CpG dinucleotides during semi-conservative DNA replication leads
to trapping of DNMT1 and consequent conversion of the 5mC in
such hemi-methylated CpGs to its downstream derivatives by TETs
(Figure 5). Our findings suggests that the advent of TET proteins
Figure 4 | FCS measurement of TET-CD dynamics in MCF7 cells upon DAC treatment. (a) Representative autocorrelation function of TET-CD-GFP
protein dynamics in early stage of DAC treatment. (b) Representative autocorrelation function of TET-CD-GFP protein dynamics in late stage of DAC
treatment. (c) The percentage of bound TET-CD-GFP was calculated at different time points (n . 40 measurements for each point). (d) The
corresponding changes of 5mC and 5hmC were determined after 40 hours of DAC treatment.
www.nature.com/scientificreports
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following DNMT1 trapping and degradation, can be due to their
enzymatic preference for hemi-methylated CpGs, which are
increased in abundance following DAC administration. Following
these lines of experiments, we further validated the similar changes of
5mC and 5hmC in TK6 and MCF7 cells upon DAC treatment
(Supplementary Figure 5).
Finally, we believe that our observations have important implica-
tions in the putative therapeutic mechanism of action of hypomethy-
lating agents currently in clinical usage in MDS and AML.
Hematological cancers are characterized by recurrent mutations in
genes involved in the regulation of DNAmethylation, notably TET2,
IDH1/2 andDNMT3A.Our data suggest that in trying to understand
the biological effects of DAC and related epigenetic therapies in
certain cancers, we must consider the effects of the drug on the levels
of 5mC and its downstream derivatives, and propose that 5hmCmay
serve as an useful biomarker to monitor the clinical success of
patients administered with such epigenetic therapies.
Methods
Cell culture andDAC treatment.HL-60 cells (a kind gift of Dr. AnnRundell, Purdue
University) and TK6 cells were grown in RPMI medium (Life Technologies) and
supplemented with 10% fetal bovine serum (Atlanta Biologicals Inc) and 1%
Penicillin- Streptomycin (Life Technologies). MCF7 cells were routinely cultured
with DMEM/F-12 based medium. The cells were incubated for 24 hours in media
prior to treatment with 0.5, 1, 3 and 5 mMDAC for 40 hours (Sigma-Aldrich Corp).
All experiments were replicated at least 3 times. Cell viability was calculated by
Trypan blue exclusion staining (Supplementary Figure 3).
DNA, RNA and protein extraction. Genomic DNA, total RNA and proteins were
extracted from control and DAC treated HL-60 using standard protocols. Briefly,
genomic DNA was extracted by DNeasy Blood &Tissue kit (Qiagen), total RNA
extracted by RNeasy Mini Kit (Qiagen) and total proteins by RIPA buffer (Thermo
Fisher Scientific) following manufacturer’s instructions.
Quantitative analysis of 5mC, 5hmC, 5fC and 5caC by Enzyme-Linked
Immunoassay (EIA). The quantitation of 5mC and its demethylation derivatives
were performed by the EIA platform developed in our lab and as described
previously28.
Quantitative analysis of 5mC and 5hmC by LC-MS/MS. Genomic DNA was
digested into constituent nucleosides using a nuclease mix (Zymo Research, Irvine,
CA) and chromatographic separation of nucleosides was performed using an Agilent
1200 HPLC system with a Waters Atlantis T3 (2.1 3 150mm, 3.5 mm) reversed-
phase column, with a flow rate of 0.3ml/min at ambient temperature. The mobile
phase consisted of A (0.1% formic acid in water) and B (0.1% formic acid in
acetonitrile), starting with 0% B for 2minutes, with a linear gradient of 0–10% B from
2–8 minutes, with a linear gradient of 10–60% B from 8–10 minutes, a hold at 60%B
from10–12minutes. Column re-equilibrationwas performed of 60–0%B from12–13
minutes, with a 0% B hold from 13–23 minutes. Online mass spectrometry detection
was performed using an Agilent 6460 triple quadrupole mass spectrometer, utilizing
positive electrospray ionization mode. The deoxyribonucleosides were evaluated by
Multiple Reaction Monitoring using the indicated mass transitions: 228.2R 112.1
(dC), 242.2R 126.1 (5mdC), 258.2R 142.1 (5hmdC), 256.1R 140.1 (5fdC) and
272.1R 156.1 (5cadC). 5mdC, 5hmdC and dC were quantitated using calibration
curves generated from authentic standards. The linear range and limits of detection
are listed in Supplementary Table 1. Limits of Detections (LODs) of 5mdC and
5hmdC (0.09 and 0.11 fmol respectively) were comparable to the LODs obtained by
themost sensitive LC-MS/MSmethod (devised byChen et al50). 5fdC and 5cadCwere
computed on the basis of peak areas since authentic standards were not commercially
available.
Immunocytochemistry (ICC).HL-60 cells were fixed in 4%paraformaldehyde for 15
minutes. The cells were then washed with cold PBS and smeared on poly-L lysine
coated coverslip. The cells were then permeabilized for 15minutes with cold PBS
containing 0.4% Triton X-100. Permeabilized cells were then washed and denatured
with 2NHCl for 15minutes, neutralized with 100mMTris-HCl (pH 8.5) for 10min.
The cells were then incubated for 1 hour with blocking buffer (10% goat serum, 3%
bovine serum albumin in PBS containing 0.1% Triton X-100) before incubation with
primary antibodies [For 5mC (Eurogentec) or 5hmC (Active Motif)] overnight at
4uC. After three consecutive 5-min washes with PBS, cells were incubated with
secondary antibodies for 30minutes. Cells were washed again three times with PBS
and then mounted in fluorescent mounting medium (Vector Laboratories). Images
were acquired using Nikon A1R multiphoton microscope and analyzed by Nikon
software.
Quantitative RT-PCR (qRT-PCR). cDNA was generated from total RNA extracted
from cells with Quantitect Reverse Transcription Kit (Qiagen). qRT-PCR reactions
were performed on an ABI PRISM StepOnePlus Real-Time PCR system (Applied
Biosystems) using SYBR Green reagent (Life Technologies) or Taqman dye (Life
Technologies). cDNA levels of target genes were analyzed using comparative Ct
methods, where Ct is the cycle threshold number, and normalized to GAPDH. PCR
Figure 5 | Our proposed model to explain the increase of 5hmC, 5fC and 5caC upon DAC treatment. The TET proteins appear to be partially selective
for hemi-methylated CpGs, and in absence of DNMT1 (due to covalent binding with DAC), can convert the hemi-methylated CpGs into hemi-
hydroxymethylated, hemi-formylated or hemi-carboxylated CpGs. Semi-conservative DNA replication in the presence of DAC may give rise to a
condition where some methylated-CpGs incorporate DAC in place of Cytidine in the newly synthesized strand while the parent strand maintains the
original 5mCmark (i.e. resulting in 5mC-G/G-DACdinucleotide). In absence ofDNMTs (DAC induced trapping and degradation) or knowledge of non-
TETmediated active demethylation pathway in mammalian cells, it may be likely that the TETs can act on the 5mC of the parent strand, converting it to
the other derivatives in the active demethylation pathway (5mC-G/G-DACR 5hmC-G/G-DACR 5fC-G/G-DACR 5caC-G/G-DAC). Similarly, 5hmC
or 5fC of the hydroxymethylated-CpGs and formylated-CpGs respectively incorporating DAC in the daughter strand could get converted to downstream
derivatives of the pathway.
www.nature.com/scientificreports
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primers are listed in Supplementary Table 2. Taqman probes for TET1, 2, 3 were
purchased from Life Technologies.
Western blot. 30 mg of cell lysates were analyzed on 8% Tris-Glycine polyacrylamide
gels (Invitrogen) and transferred to PVDF membrane using BioRad mini transfer
apparatus for 1.5 hour at 50 V. Membrane was blocked with 5%milk for one hour in
room temperature and probed with Rabbit polyclonal anti-DNMT1 (Abcam,
151000), DNMT3A (Abcam, 15500), DNMT3B (Abcam, 15500), b-actin (Abcam,
15500), Tet1 antibody (Abcam, 151000) or mouse monoclonal anti-TET2 (Active
Motif 15500) for overnight at 4uC. This was followed bywashes in PBST (0.5%Tween
20) and incubation in HRP-conjugated secondary antibodies (Cal Biochem). Blots
were developed using ECL reagent (GE Healthcare).
Mathematical analysis. In the most recent mathematical model of DNA
methylation29 the relative activities of the various proteins are represented by a series
of constants (k1, k2, k3, k4, and k5). These constants characterize the flow between six
compartments, each representing a discrete epigenetic CpGmodification. In brief, k1
represents the combined activity of DNMT3A and DNMT3B to generate hemi-
methylated CpG dinucleotides, k2 the activity of DNMT1 to generate fullymethylated
CpG dinucleotides, and k3-k5 the activity of TET to perform hydroxymethylation on
hemi-methylated, fully methylated, and hemi-hydroxymethylated and hemi-
methylated (5hmC/5mC) CpG dinucleotides respectively. The complete model
comprises a set of first order, partial differential equations which can be solved via
numerical integration.
In machina treatment with DACwas modeled as elimination of DNMT1 activity i.
e. as k25 0. To test the hypothesis that selective activity of TET for hemi-methylated
dinucleotides could explain the apparently paradoxical increase in hydroxymethy-
lation the hydroxymethylation constants k3 and k4 were varied. Where TET was
defined as being fully selective for hemi-methylated dinucleotides a value of k45 0. In
models where TET was defined as being partially selective for hemi-methylated
dinucleotides, the relative values of the hydroxymethylation constants were varied
such that k3 . k4. When using a value of k1 5 0.2 (consistent with previous mod-
els29,43) a value of k3/k4 of 0.5 or greater was found to produce an increase in hydro-
xymethylation when DAC treatment was applied (although at the lower k3/k4 values
this increase was transient). We found that modification of k5 had minimal effect on
the model which is likely a result of the relatively small abundance of hemi-hydro-
xymethylated hemi-methylated (hmC/mC) dinucleotides. All models were analyzed
using fourth order Runge-Kutta numerical integration.
In order to extend the model to incorporate the downstream products of TET
activity 5fC and 5caC two additional partial differential equations were incorporated
into the existing model. The first enables calculation of the change in abundance of
5fC (x7) in the cell population given the abundance of 5hmC/5mC (x4), 5hmC/5hmC
(x5), and 5hmC/C (x6):
Lx7
Lt
~c1 x4z2x5zx6ð Þ{ c2zlð Þx7 ð1Þ
where c1 is the conversion rate constant of 5hmC to 5fC, c2 is the conversion rate
constant of 5fC to 5caC, and l is the cell loss rate. The second equation enables
calculation of the change in abundance of 5caC (x8) in the cell population given of the
abundance of 5fC (x7):
Lx8
Lt
~c2x7{lx8 ð2Þ
As the relative abundance of 5fC and 5caC is very small11 no changes weremade to the
existing system of equations assuming thatmovement of dinucleotides into and out of
these two new model compartments will have a negligible impact on the far greater
abundances of the other types of dinucleotide. Values of c1 5 0.00352 and c2 5
0.0288 were selected to give abundances of 1565 and 15430 for 5fC and 5caC
respectively relative to 5hmC in the steady state, as reported for murine ES cells11.
When in machina DAC treatment was applied to this extended model 5fC and 5caC
abundances increased in tandem with 5hmC abundance when TET was selective for
hemi-methylated dyads.
TET1-CD-GFP construct and transfection. The fusion protein of TET1 catalytic
domain (TET1-CD) and EGFP was generated by sequentially assembling the coding
sequences of the desired proteins using standard restriction enzyme digest and
ligation method. The inserts are incorporated into the pShooterTM mammalian
expression vector (V821-20, Life Technologies). Prior to the incorporation of inserts,
an adapter molecule was introduced in the multiple cloning sites (MCS) of the vector
with NcoI and PstI flanking at the 59 and 39 end respectively. Briefly, the adapter
molecule was generated by annealing the equimolar concentration of the primers UP:
59-CATGGATCCGAGGCGCGCCGCTAGCGGTACCCTGCA-39 and LP: 59-
GGGTACCGCTAGCGGCGCGCCTCGGATC-39 at 50uC for 10 min. The adapter
thus made was ligated to the vector after double digestion with NcoI and PstI. This
adapter molecule introduced new restriction sites to the vector, including BamHI,
AscI, NheI, KpnI, and SfbI. The source plasmids of TET1 (#49792 from Anjana Rao
lab), and EGFP (#23027 from Andrea LeBlanc lab) were obtained from the Addgene
plasmid repository (https://www.addgene.org). EGFP and catalytic domain of TET1-
CDwere PCR amplified with desired restriction sites flanking on either side, from the
respective source plasmids. Suitable linker molecules were included to the primer
sequences, where needed. The PCR reaction was carried out as specified by the
manufacturer (CloneAmpHiFi PCR Premix; Clontech) for the template DNA
concentration . 100 ng with 35 cycles of amplification. Details of the PCR primers
have been summarized in Supplementary Table 3. Digested PCR amplicons were gel
purified using the QIAEX II gel extraction kit (Qiagen). Purified vector and inserts
thus made were ligated along with requisite amount of T4 ligase buffer and T4 DNA
ligase (New England Biolabs) and kept at room temperature for 15 minutes. The
ligated products were then transformed into the stellarTM competent cells (PT5056-2,
Clontech) and plated out onAmpicillin containing LB agar plate. Suitable clones were
propagated and the plasmids were extracted with QIAprep Spin Miniprep Kit
(Qiagen).MCF7 cells for transfection were seeded on sterilizedNo.1 coverslips (VWR
International) in a 12-well plate. After reaching 70% of cell confluence the medium
was replaced with antibiotic-free, low-serum medium for another 12 hours. Then
400 ng of plasmid DNA was added to the culture with LipofectamineH LTX
transfection reagents (Life Technologies). Transfection efficacy was tested after
24 hours prior to the single-molecule measurements.
FCS measurement of TET1-CD-GFP after DAC treatment. The intracellular
dynamics of TET1-CD-GFP upon 3 mM DAC treatment was measured by FCS in a
scanning confocal time-resolved system (Microtime200, Picoquant). A 465-nm
picosecond pulsed diode laser was delivered through a 603 water immersion
objective (N.A.5 1.2) to excite the GFP tag. The emitted fluorescence was collected
by single photon avalanche photodiode detector (SPAD, PerkinElmer) and stored in
time-correlated single-photon counting (TCSPC) module. The iteration of the
autocorrelation function G(t) for FCS is based on:
G tð Þ~ dF tð ÞdF tztð Þh i
F tð Þh i2 ð3Þ
where F is the fluorescence intensity; t is the time delay. To obtain the diffusion state
of TET-CD-GFP, a 3D two-component diffusing model was applied:
G(t)~
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where N is the average number of molecules, y is the percentage of bound TET-CD-
GFP, tD is the diffusion time, and k is the excitation profile.
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